Allogene Therapeutics reported financial results for the quarter ended June 30, 2026, posting a net loss of $42.7 million, or $0.13 per share. The company held $423.6 million in cash and investments as of June 30, 2026, projecting its cash runway into 2029. In clinical developments, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for cemacabtagene ansegedleucel (Cema-Cel) following a positive interim futility analysis in the Phase 2 ALPHA3 trial for large B-cell lymphoma. The company accelerated its site activation target to approximately 100 sites by year-end, with enrollment expected to complete by late 2027. Additionally, brisk enrollment continues in the Phase 1 RESOLUTION trial for ALLO-329 in autoimmune disease, with a clinical update anticipated in Q4 2026. Allogene Therapeutics is a clinical-stage biotechnology company pioneering allogeneic CAR T products for cancer and autoimmune diseases.

At its 2026 Annual Meeting of Stockholders, Allogene Therapeutics, Inc. stockholders' approved an amendment to the Certificate of Incorporation to increase the number of authorized shares from 400,000,000 to 800,000,000, effective June 18, 2026. Additionally, the company has filed a prospectus supplement to sell common stock with an aggregate offering price of up to $135.0 million. Allogene Therapeutics, Inc. is a biotechnology company focused on on-cell therapy.</div>